Cereno Scientific (CRNO-B.ST)

Executive Summary

Cereno Scientific is a Swedish biopharmaceutical company focused on developing disease-modifying treatments for rare cardiovascular and pulmonary diseases. Its lead candidate, CS1 (a histone deacetylase inhibitor), targets Pulmonary Arterial Hypertension (PAH), a severe condition with high unmet need. CS1 completed a Phase 2 trial (NCT05224531) in PAH in August 2024, demonstrating a favorable safety profile and potential efficacy in reducing mean pulmonary arterial pressure. The company also has a Phase 1 completed study for CS1 in thrombosis and an active preclinical program for a new CS1 formulation in PAH. With a market capitalization around $1.9 billion, Cereno is positioned to advance its pipeline toward registrational studies. The upcoming milestones include the initiation of a Phase 3 trial for CS1 in PAH, leveraging the Phase 2 data to design a pivotal study. Additionally, the company may explore strategic partnerships for its thrombosis program and further preclinical results for CS1 expansions. Despite the promising early data, the company remains at an early stage, with regulatory and clinical risks ahead. However, the strong need for effective PAH therapies and the potential of CS1's novel mechanism support a moderate conviction in its long-term prospects.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 3 trial for CS1 in Pulmonary Arterial Hypertension75% success
• 2026Preclinical data update for CS1 in new indications or formulations60% success
• TBDPotential partnership or licensing deal for CS1 in thrombosis40% success